These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9449120)

  • 21. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technology evaluation: APC-8015, Dendreon.
    Rini BI
    Curr Opin Mol Ther; 2002 Feb; 4(1):76-9. PubMed ID: 11883698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
    Delcayre A; Shu H; Le Pecq JB
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technology evaluation: DCVax, Northwest Biotherapeutics.
    Knutson KL
    Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cell-based tumor immunotherapy.
    Kadowaki N; Kitawaki T
    Rinsho Ketsueki; 2009 May; 50(5):358-63. PubMed ID: 19483395
    [No Abstract]   [Full Text] [Related]  

  • 28. Dendritic cells: a journey from laboratory to clinic.
    Cerundolo V; Hermans IF; Salio M
    Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398
    [No Abstract]   [Full Text] [Related]  

  • 29. [Dendritic cells: orchestration of the immune response].
    Martinon-Ego C; Berthier R
    Ann Biol Clin (Paris); 2000; 58(5):541-56. PubMed ID: 11022098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Peptide-pulsed dendritic cell therapy].
    Takaue Y; Tanosaki R; Tobisu K
    Nihon Rinsho; 2000 Jul; 58 Suppl():295-8. PubMed ID: 11022733
    [No Abstract]   [Full Text] [Related]  

  • 31. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
    Lin AM; Hershberg RM; Small EJ
    Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.
    Dietz AB; Litzow MR; Gastineau DA; Vuk-Pavlović S
    Croat Med J; 2001 Aug; 42(4):428-35. PubMed ID: 11471194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
    Kalady MF; Onaitis MW; Padilla KM; Emani S; Tyler DS; Pruitt SK
    J Surg Res; 2002 Jun; 105(1):17-24. PubMed ID: 12069496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunotherapy].
    Yoshimura K; Uemura H
    Nihon Rinsho; 2016 May; 74 Suppl 3():238-43. PubMed ID: 27344735
    [No Abstract]   [Full Text] [Related]  

  • 36. Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer.
    Belldegrun A; Bander NH; Lerner SP; Wood DP; Pantuck AJ
    J Urol; 2001 Oct; 166(4):1316-21. PubMed ID: 11547065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials.
    Salgaller ML; Thurnher M; Bartsch G; Boynton AL; Murphy GP
    Cancer; 1999 Dec; 86(12):2674-83. PubMed ID: 10594863
    [No Abstract]   [Full Text] [Related]  

  • 38. Lentivector targeting to dendritic cells.
    Ageichik A; Collins MK; Dewannieux M
    Mol Ther; 2008 Jun; 16(6):1008-9. PubMed ID: 18500241
    [No Abstract]   [Full Text] [Related]  

  • 39. [The possibility and limitations of cell therapy. 2) The current status and overview of tumor-immune cell therapy--T cell-dendritic cell therapy].
    Kawakami Y
    Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1923-8. PubMed ID: 17929434
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?
    Karan D
    Immunotherapy; 2013 Sep; 5(9):907-10. PubMed ID: 23998723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.